{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016171","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.216186+00:00","generated_at":"2026-06-10T06:47:42.996402+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Capricor raises $23M in registered direct offering of stock and warrants","bullets":["Gross proceeds ~$23M from 4,935,621 shares plus warrants at $4.66/unit.","Warrants exercisable at $5.70/share for 7 years, beginning 6 months after issuance.","Investors include Nippon Shinyaku and Highbridge Capital Management.","Net proceeds to fund R&D, manufacturing, working capital; expected to fund HOPE-3 Phase 3 topline data readout."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016171","json":"https://secwatch.observer/filing/0001558370-23-016171.json","markdown":"https://secwatch.observer/filing/0001558370-23-016171.md","text":"https://secwatch.observer/filing/0001558370-23-016171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023016171/0001558370-23-016171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023016171/capr-20230929x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:47:42.996402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8108764e2b1d052beb5191246d117993c8c3f581","claim":"CAPRICOR THERAPEUTICS, INC. entered into Purchase Agreement with certain institutional investors valued at approximately $23 million (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Offering”), an aggregate of (a) 4,935,621 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), (the “Shares”) and (b) warrants to purchase 4,935,621 shares of the Company’s common stock (the “Warrants”) to the Purchasers.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023016171/0001558370-23-016171-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $23 million"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}